Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell Lung Cancer

• Published in: Anticancer research Vol. 41; no. 4; pp. 1871 - 1882
• Main Authors: Mon, May Myat, Srisomsap, Chantragan, Chokchaichamnankit, Daranee, Watcharatanyatip, Kamolwan, Weeraphan, Churat, Svasti, Jisnuson, Maneechai, Kajornkiat, Thongsuksai, Paramee, Raungrut, Pritsana
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.04.2021
• Subjects: A549 Cells; Aged; Aged, 80 and over; Antibodies; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - blood; Carboplatin; Carboplatin - therapeutic use; Carcinoma, Non-Small-Cell Lung - blood; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Clinical Decision-Making; Drug Resistance, Neoplasm; Female; Gene expression; Glycoproteins; Humans; Liquid chromatography; Lung cancer; Lung Neoplasms - blood; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Mass spectrometry; Mass spectroscopy; Middle Aged; Non-small cell lung carcinoma; Orosomucoid - analysis; Paclitaxel; Paclitaxel - therapeutic use; Predictive Value of Tests; Proteins; Proteomics; Small cell lung carcinoma; Treatment Outcome; Western blotting; non-small cell lung cancer; paclitaxel; Serum; proteomic; carboplatin
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.14953

This study aimed to identify differentially expressed proteins in the serum of advanced non-small cell lung cancer (NSCLC) patients responding to carboplatin (CAR) plus paclitaxel (PTX) chemotherapy compared to non-responders. Serum from 8 responders and 6 non-responders was subjected to proteomic analysis by label-free liquid chromatography tandem mass spectrometry and validated by western blotting. CAR/PTX-resistant human H1792 and A549 cells were used for evaluating gene expression. Fifty-two proteins were differentially expressed between responders and non-responders. Alpha 1 antitrypsin antibody, alpha 1 acid glycoprotein (A1AG1), afamin, protein S100-A9 and immunoglobulin heavy constant gamma 3 (IGHG3) were validated. IGHG3 was elevated (p=0.037) while A1AG1 was reduced (p=0.003) in responders as compared to non-responders. Gene expression of IGHG3 and ORM1 in resistant cells showed consistent results with the proteomics profiles. Serum expression levels of IGHG3 and A1AG1 proteins may be useful to recruit an NSCLC subpopulation that can benefit from CAR plus PTX standard therapy.